AVADEL PHARMACEUTICALS (AVDL) Stock Income Statement
NASDAQ:AVDL - Nasdaq - IE00BDGMC594 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 194.45M | 169.12M | 27.96M | 0.00 | 0.00 | |||
| Cost Of Goods | 19.33M | 15.28M | 846.00K | N/A | 0.00 | |||
| Gross Profit | 175.12M | 153.84M | 27.12M | N/A | 0.00 | |||
| Operating Expenses | 194.48M | 196.24M | 164.97M | 95.22M | 85.60M | |||
| Research and Development | 16.48M | 15.20M | 13.26M | 20.70M | 17.10M | |||
| Selling, General, and Administrative Expenses | 178.00M | 181.04M | 151.71M | 74.52M | 68.50M | |||
| Operating Income | -19.37M | -42.40M | -137.85M | -95.22M | -85.60M | |||
| Interest Income/Expense | -10.48M | -10.83M | -9.89M | -12.34M | -9.94M | |||
| Other Income/Expense | 3.17M | 4.15M | 87.00K | -536.00K | 2.34M | |||
| Non Recurring Items | N/A | 0.00 | -13.13M | -3.35M | 53.00K | |||
| Income Before Taxes | -26.67M | -49.08M | -160.78M | -111.44M | -93.14M | |||
| Income Tax | -263.00K | -247.00K | -501.00K | 26.02M | -15.82M | |||
| Net Income | -26.41M | -48.83M | -160.28M | -137.46M | -77.33M | |||
| EBITDA | -16.40M | -39.72M | -136.08M | -93.72M | -84.78M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.29 | -0.55 | -2.13 | -2.44 | -1.41 | |||
| Non GAAP EPS | -0.27 | -0.52 | -2.01 | -2.25 | -1.32 | |||
| Statistics | ||||||||
| Gross Profit Margin | 90.06% | 90.97% | 96.97% | N/A | N/A | |||
| Profit Margin | -13.58% | -28.87% | -573.17% | N/A | N/A | |||
| Operating Profit Margin | -9.96% | -25.07% | -492.97% | N/A | N/A | |||
All data in USD